7-Hydroxymitragynine Dosage Guide

Why 7-OH is dosed in milligrams, not grams

In animal work, oral 7-OH produced antinociception at roughly a tenth of the morphine-equivalent dose and a fraction of what mitragynine required (Matsumoto 2004; Kruegel 2016). A typical kratom serving of several grams of leaf delivers on the order of a few milligrams of mitragynine, of which only a fraction is converted to 7-OH in vivo via CYP3A4 (Kruegel 2019). A single 10 mg 7-OH tablet bypasses that conversion step and delivers, as a pharmacologically active dose, more 7-OH at the receptor than a full session of leaf kratom.

Practically: a dose range that is routine for kratom powder (2–8 g) is not a reference point for 7-OH products. Treat 7-OH as its own compound with its own scale.

User-reported dose ranges

These ranges reflect what experienced users and vendor product labelling describe — not clinical recommendations. No controlled human dose-finding study for isolated 7-OH has been published, so any figure cited online (including below) is extrapolated from preclinical pharmacology and self-report.

Onset and duration

Human pharmacokinetic work on mitragynine shows a long terminal half-life — about 24 hours in chronic users (Trakulsrichai 2015). No equivalent controlled PK data exists for isolated 7-OH in humans, but the animal literature and user reports converge on a practical picture: onset within 20–45 minutes for oral tablets and gummies, 10–20 minutes for sublingual or shot formats, with peak effects at 60–90 minutes and an experiential duration of two to four hours before the tail. The long PK half-life of the parent alkaloid is the mechanism behind next-day residual effects at high or frequent doses.

Building a personal threshold

Because individual CYP3A4 activity, body composition, and baseline opioid tolerance all change the effective dose at the receptor, published ranges are a starting prior — not a prescription. A conservative protocol:

• Start below the beginner range — a quarter or half of the lowest commercial tablet (often 1–3 mg) — and take it on an empty stomach with a known baseline (no alcohol, no other opioids, no CYP3A4 inhibitors like grapefruit or ritonavir).
• Wait at least 90 minutes before considering more. Effects ramp slowly enough that stacking doses early almost always leads to overshoot.
• Record dose, format, timing, and effect for the first several sessions. Personal threshold usually stabilises within five to ten exposures; without notes, it will not.
• Increase by no more than 25% per session when titrating up.

Daily use and tolerance

There is no established safe daily dose for 7-hydroxymitragynine. Regular kratom users develop measurable physical dependence and a withdrawal syndrome that parallels classical opioid withdrawal in symptom structure (Singh 2014), and concentrated 7-OH products are expected to shorten the time to dependence relative to leaf. Patterns that reduce but do not eliminate that risk: capping total weekly exposure, alternating non-dosing days, and avoiding the pattern of redosing to extend effects. Full mechanism and timeline on the withdrawal page.

Dosing by product format

Milligram content on the front of a package is not the same as milligrams delivered to receptors. Differences across formats come from absorption route (sublingual vs. oral first-pass), the ratio of mitragynine to 7-OH in the product, and — most importantly — whether the label matches the actual content. Independent lab testing of 7-OH products has repeatedly found label variance; request and read a Certificate of Analysis (COA) for each lot.

• Tablets— commercially labelled at 5–80 mg per tablet; scored tablets allow halving or quartering for low-threshold dosing.
• Shots — liquid formats vary widely in concentration. Check total mg per bottle and do not assume the full bottle is one dose.
• Gummies — lower per-unit doses but slower, less predictable onset due to food-matrix absorption.
• Powder— requires a 0.001 g (milligram) scale. Volumetric dosing (eyeballing or using a spoon) is not accurate at the milligram scale and is the most common cause of accidental overshoot.

Interactions and contraindications

Do not combine 7-OH with alcohol, benzodiazepines, other opioids, gabapentinoids, or other CNS depressants — the respiratory-depression risk compounds, and fatal overdoses reported in US surveillance data overwhelmingly involve polydrug exposure (CDC MMWR 2019; Post 2019). CYP3A4 inhibitors and inducers (common prescription antifungals, some HIV antivirals, grapefruit juice) materially change 7-OH exposure from mitragynine-containing products (Kamble 2020); the effect on pre-formed isolated 7-OH is smaller but not zero. Full adverse event profile on the side effects page.